Reo Inoue

Dr. Reo Inoue

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Life
Verified
Journal Article
Open access
PDF file
RTRikuhei Tsuchida
Rikuhei Tsuchida
MSMasahiko Sumitani
Masahiko Sumitani
HAHiroaki Abe
Hiroaki Abe
MAMasae Ando
Masae Ando
KSKosuke Saita
Kosuke Saita
KUKanji Uchida
Kanji Uchida
The purinergic P2Y12 receptor regulates microglial activation, resulting in persistence and aggravation of pain in neuropathic and nociceptive pain models. We conducted a retrospective chart review to explore the analgesic potency of the P2Y12 receptor-specific antagonist, clopidogrel, for clinical management of postoperative pain in patients who underwent abdominal surgery. Twenty-seven patients with cardiovascular comorbidities, who underwent laparoscopic abdominal surgery and had ceased aspirin (ASP, n = 17) or clopidogrel (CLP, n = 10) for 14 days pre-operatively, were enrolled retrospectively. In both groups, the number of opioids and non-steroidal anti-inflammatory drugs (NSAIDs) consumed for managing postoperative pain was compared using the chi-square test and Mann–Whitney test. Our results showed that from postoperative day (POD) 0 to POD 3, the average numerical rating reflecting the postoperative pain was comparable between the two groups (CLP: 4.0 ± 1.4 vs. ASP: 3.7 ± 0.8, P-value = 0.56). However, at POD 7, opioid consumption in the CLP-treated group (fentanyl-equivalent dose: 0.49 ± 0.56 mg) was significantly lower than that in the ASP-treated group (1.48 ± 1.35 mg, P-value = 0.037). After reaching a stable state by repeated systemic administration, clopidogrel sustained the analgesic efficacy for a certain period. In conclusion, microglial P2Y12 receptors may mediate signal transduction of postoperative nociceptive pain and enhance clinical opioid analgesia.

25 June 2025 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
MSMizuho Sumitani
Mizuho Sumitani
TKTakamichi Kogure
Takamichi Kogure
HAHiroaki Abe
Hiroaki Abe
RTRikuhei Tsuchida
Rikuhei Tsuchida
RIReo Inoue
Reo Inoue
MSMasahiko Sumitani
Masahiko Sumitani
Background and Aim: Neuropathic pain leads to a significant deterioration in health-related quality of life (HRQOL). Treating neuromusculoskeletal pain is especially important to prevent and improve physical frailty and the locomotive syndrome. Varied pharmacotherapies could be applicable for neuropathic pain patients, but evidence has been limited for a wide range of neuropathic pain conditions with different etiologies. The aim of this review was to highlight mirogabalin, a novel calcium channel α2δ ligand which was first approved in Japan, and which is effective for various types of neuropathic pain diseases. Methods: We conducted a narrative review of the recent evidence that mirogabalin has significant analgesic potency for varied types of neuropathic pain conditions. Futher, this review highlighted specific advantages over other calcium channel ligands. Results: Analgesic potency of mirogabalin could cover peripheral neuropathic pain conditions including post-herpetic neuralgia, diabetic peripheral neuropathy, cauda equina syndrome caused by lumbar spinal stenosis, radiculopathy caused by cervical spondylosis, and also central neuropathic pain conditions like spinal cord injury. Mirogabalin consistently demonstrated daytime sleepiness and dizziness as adverse effects, but most of these were mild. Conclusions: Mirogabalin is recommended as the first-line drug against most molecular mechanisms that cause neuropathic pain regardless of whether they have a peripheral or central origin. Mirogabalin demonstrates relatively less daytime sleepiness, making it age-friendly in the current global situation where population aging is accelerated. Considering the epidemic of ‘opiophobia’ in Japan and other countries, pharmacotherapy using mirogabalin could treat neuropathic pain associated with cancer and its treatment (e.g., chemotherapy-induced peripheral neuropathy), as well as non-cancer etiologies worldwide.

9 September 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
YTYuki Taniguchi
Yuki Taniguchi
HNHideki Nakamoto
Hideki Nakamoto
SKSo Kato
So Kato
Hiroyuki NakaraiHiroyuki Nakarai
Hiroyuki Nakarai
KNKosei Nagata
Kosei Nagata
KFKazuhiko Fukatsu
Kazuhiko Fukatsu
Background/Objectives: Malnutrition, which is closely associated with frailty and sarcopenia, is common in older adults and is linked to adverse perioperative complications in musculoskeletal surgery. However, its influence on postoperative health-related quality of life (HRQOL) remains unclear. This study aimed to investigate the impact of preoperative malnutrition on HRQOL one year after surgery in elderly patients with degenerative cervical myelopathy (DCM). Methods: We retrospectively analyzed 188 patients aged ≥ 65 years who underwent elective surgery for DCM between 2017 and 2024. Preoperative nutritional status was assessed using the Geriatric Nutritional Risk Index (GNRI), with GNRI ≤ 98 indicating malnutrition risk. Patient-reported outcome measures were assessed using the EuroQol Five-Dimension Questionnaire (EQ-5D) both preoperatively and at one year postoperatively. The minimum clinically important difference (MCID) threshold was applied to evaluate significant changes. Multivariate logistic regression was used to identify independent risk factors for postoperative deterioration in EQ-5D score. Results: Of the 188 patients, 35 were classified as having malnutrition risk. While preoperative EQ-5D scores were comparable between the two groups, the postoperative EQ-5D score was significantly lower in the malnutrition risk group than in the no-risk group (0.58 vs. 0.67, p = 0.003). Deterioration in EQ-5D scores exceeding the MCID threshold occurred more frequently in the malnutrition risk group (37.1% vs. 21.2%, p = 0.049). Furthermore, multivariate analysis identified preoperative GNRI ≤ 98 as an independent risk factor for deterioration in EQ-5D score exceeding the MCID threshold (OR 2.40, 95% CI 1.03–5.52). Conclusions: Preoperative malnutritional status was significantly associated with impaired postoperative HRQOL in elderly patients with DCM. These findings highlight the need for preoperative nutritional assessment and optimization in this vulnerable population.

1 August 2021 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
RTRikuhei Tsuchida
Rikuhei Tsuchida
YTYuko Tanabe
Yuko Tanabe
DNDaisuke Nishizawa
Daisuke Nishizawa
KIKazutaka Ikeda
Kazutaka Ikeda
HAHiroaki Abe
Hiroaki Abe
MSMasahiko Sumitani
Masahiko Sumitani

29 July 2022 in Medicine
Verified
Journal Article
Open access
KMKazuhito Mietani
Kazuhito Mietani
MHMaiko Hasegawa-Moriyama
Maiko Hasegawa-Moriyama
RIReo Inoue
Reo Inoue
TOToru Ogata
Toru Ogata
NSNobutake Shimojo
Nobutake Shimojo
MSMasahiko Sumitani
Masahiko Sumitani
Postoperative delirium is a common complication for elderly patients. Detection of phosphorylated neurofilament heavy subunit in the serum reflects axonal damage with postoperative delirium. Although it has been implicated that serum apolipoprotein levels might be associated with senile cognitive disorder, its role in the development of delirium has not been fully investigated. This study examined the association of apolipoproteins with delirium after surgery. This was a post hoc analysis of 117 patients who participated in a prospective observational study of delirium in patients undergoing cancer surgery. Patients were clinically assessed for delirium within the first 5 days of surgery. Serum levels of apolipoprotein A-I, B, and E were measured on postoperative day 3. Forty-one patients (35%) were clinically diagnosed with postoperative delirium. Serum levels of apolipoprotein A-I and B were increased in patients with delirium whereas those of apolipoprotein E were decreased. These changes in apolipoprotein A-I and E levels were associated with the presence of phosphorylated neurofilament heavy subunit in the serum, and were significantly associated with delirium (A-I: adjusted odds ratio [aOR], 6.238; 95% confidence interval [CI], 2.766–20.68; P < .0001; E: aOR, 0.253; 95% CI, 0.066–0.810; P = .0193). A combination of apolipoprotein A-I and E offers significant discrimination between delirium and nondelirium with high accuracy (area under the curve, 0.8899). Serum apolipoprotein A-I and E levels were associated with delirium and the presence of phosphorylated neurofilament heavy subunit in serum. Therefore, apolipoproteins might be useful biomarkers of postoperative delirium.

28 May 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
RIReo Inoue
Reo Inoue
MSMasahiko Sumitani
Masahiko Sumitani
AKAtsushi Kimura
Atsushi Kimura
TMTakao Mochizuki
Takao Mochizuki
TAToru Akiyama
Toru Akiyama
MKMakoto Kurano
Makoto Kurano
Background/Objectives: Lysophosphatidic acid (LPA) is a bioactive lipid mediator implicated in neuropathic pain (NP). Depressive symptoms frequently accompany NP and adversely affect outcomes, yet objective biomarkers remain limited. This study aimed to identify cerebrospinal fluid (CSF) LPA molecular species associated with depressive symptoms in patients with NP. Methods: CSF samples were obtained from 48 patients, and LPA species, including positional isomers (sn-1 and sn-2), were quantified using liquid chromatography–tandem mass spectrometry. Depressive symptoms were assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Statistical analyses were performed to evaluate associations among depressive symptoms, clinical variables, and LPA species. Results: CSF LPA18:0 was significantly associated with HADS-D scores (r = 0.380, p = 0.010), with the strongest association observed for the sn-1 isoform (r = 0.385, p = 0.009). In multivariable analysis, LPA18:0 sn-1 remained independently associated with depressive symptoms, alongside pain intensity and pain catastrophizing (R2 = 0.386). Structural equation modeling supported an association between LPA18:0 sn-1 and depressive symptoms independent of pain-related factors. Conclusions: These findings suggest that CSF LPA18:0 sn-1 may be associated with a biological dimension of depressive distress and may represent a candidate biomarker of depressive distress in NP. However, these findings should be interpreted cautiously, as the analyses were exploratory, and further validation in independent and longitudinal cohorts is warranted.